![Table 1. Clinical trial enrollment patterns for multiple studies in the literature | American Cancer Society Cancer Action Network Table 1. Clinical trial enrollment patterns for multiple studies in the literature | American Cancer Society Cancer Action Network](https://www.fightcancer.org/sites/default/files/National%20Images/Resources%20Graphics/Table%201%20Clinical%20trial%20enrollment%20patterns%20for%20multiple%20studies%20in%20the.jpg)
Table 1. Clinical trial enrollment patterns for multiple studies in the literature | American Cancer Society Cancer Action Network
![Doing Our Part: Improving Diversity in Clinical Research Participation - Center for Information & Study on Clinical Research Participation Doing Our Part: Improving Diversity in Clinical Research Participation - Center for Information & Study on Clinical Research Participation](https://www.ciscrp.org/wp-content/uploads/2021/03/Picture1-1.png)
Doing Our Part: Improving Diversity in Clinical Research Participation - Center for Information & Study on Clinical Research Participation
![Clinical Trials - Grey Literature in the Health Sciences - Research Guides at University of Alabama - Birmingham Clinical Trials - Grey Literature in the Health Sciences - Research Guides at University of Alabama - Birmingham](https://s3.amazonaws.com/libapps/accounts/200/images/Grey_Lit_2.gif)
Clinical Trials - Grey Literature in the Health Sciences - Research Guides at University of Alabama - Birmingham
Evidence for the Selective Reporting of Analyses and Discrepancies in Clinical Trials: A Systematic Review of Cohort Studies of Clinical Trials | PLOS Medicine
![Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4ba8a139-a98a-4306-9ae7-443a9ad74d47/gr1_lrg.jpg)
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology
![Clinical impact and quality of randomized controlled trials involving interventions evaluating artificial intelligence prediction tools: a systematic review | npj Digital Medicine Clinical impact and quality of randomized controlled trials involving interventions evaluating artificial intelligence prediction tools: a systematic review | npj Digital Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41746-021-00524-2/MediaObjects/41746_2021_524_Fig1_HTML.png)